Genus has stated that it expects its full-year results to be "moderately ahead" of market consensus, following "better than anticipated" trading in the second half of its financial year.

The FTSE 250 animal genetics firm said that its PIC business had performed well in the year to 30 June following growth in Asia and Latin America, offsetting a weaker performance in North America due to customer disease challenges.

It added that ABS has also achieved double-digit profit growth, with continued benefits from its value acceleration programme offsetting softer customer demand and "adverse product mix driven by lower global dairy prices".

As a result, Genus now expects its full-year results to be ahead of expectations, with its adjusted profit before tax set to reach £98m.

This includes the final £5.6m milestone payment received earlier in the year from its Chinese partner, Beijing Capital Agribusiness.

It added that cash conversion in the second half of the year was "very strong", resulting in significant growth in free cash flow generation in the full-year.

Genus concluded that it is well placed as it enters the new financial year, with continued focus on delivering its strategic priorities.

Following the announcement, the firm’s share price jumped by over 5%.

It will publish its FY26 preliminary results on 10 September.

---